Modern pharmaceutical treatment of pulmonary arterial hypertension
The review is devoted to modern pharmaceutical treatment of pulmonary arterial hypertension (PAH). In 1970-80s, it was based on high-dose calcium antagonists, CA (e.g., nifedipine 240 mg/d), which were effective only in some patients with primary (idiopathic) PAH. CA were combined with digoxin, indi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2008-12-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1735 |
| _version_ | 1797882712813469696 |
|---|---|
| author | T. A. Batyraliev E. Ekinsi Z. A. Niyazova-Karben D. V. Preobrazhensky S. A. Pataraya |
| author_facet | T. A. Batyraliev E. Ekinsi Z. A. Niyazova-Karben D. V. Preobrazhensky S. A. Pataraya |
| author_sort | T. A. Batyraliev |
| collection | DOAJ |
| description | The review is devoted to modern pharmaceutical treatment of pulmonary arterial hypertension (PAH). In 1970-80s, it was based on high-dose calcium antagonists, CA (e.g., nifedipine 240 mg/d), which were effective only in some patients with primary (idiopathic) PAH. CA were combined with digoxin, indirect anticoagulants and oxygen. In 1990s, PAH therapy included prostanoids, endothelin receptor (ER) blockers and phosphodiesterase (PDE) inhibitors, which are more selective pulmonary vasodilatators than CA, and therefore are safer for long-term treatment. Prospective studies have demonstrated that continuous intravenous infusion of epoprostenol and ET receptor blocker bosentan treatment improve survival of PAH patients receiving traditional therapy. Clinical effectiveness of epoprostenol is similar to that of subcutaneously administered trepostinil, and bosentan is similar to PDE inhibitor Type 5 sildenafil. Bosentan increases the effectiveness of intravenous epoprostenol and inhaled trepostinil |
| first_indexed | 2024-04-10T03:39:02Z |
| format | Article |
| id | doaj.art-037904351ce747d78843015008f811b2 |
| institution | Directory Open Access Journal |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| last_indexed | 2024-04-10T03:39:02Z |
| publishDate | 2008-12-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj.art-037904351ce747d78843015008f811b22023-03-13T07:23:15Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252008-12-0178941041453Modern pharmaceutical treatment of pulmonary arterial hypertensionT. A. Batyraliev0E. Ekinsi1Z. A. Niyazova-Karben2D. V. Preobrazhensky3S. A. Pataraya4Медицинский центр имени Сани Конукоглы и Университет. г. ГазиантепМедицинский центр имени Сани Конукоглы и Университет. г. ГазиантепМедицинский центр имени Сани Конукоглы и Университет. г. ГазиантепУчебно-научный медицинский центр Управления делами Президента Российской Федерации, г. МоскваУчебно-научный медицинский центр Управления делами Президента Российской Федерации, г. МоскваThe review is devoted to modern pharmaceutical treatment of pulmonary arterial hypertension (PAH). In 1970-80s, it was based on high-dose calcium antagonists, CA (e.g., nifedipine 240 mg/d), which were effective only in some patients with primary (idiopathic) PAH. CA were combined with digoxin, indirect anticoagulants and oxygen. In 1990s, PAH therapy included prostanoids, endothelin receptor (ER) blockers and phosphodiesterase (PDE) inhibitors, which are more selective pulmonary vasodilatators than CA, and therefore are safer for long-term treatment. Prospective studies have demonstrated that continuous intravenous infusion of epoprostenol and ET receptor blocker bosentan treatment improve survival of PAH patients receiving traditional therapy. Clinical effectiveness of epoprostenol is similar to that of subcutaneously administered trepostinil, and bosentan is similar to PDE inhibitor Type 5 sildenafil. Bosentan increases the effectiveness of intravenous epoprostenol and inhaled trepostinilhttps://cardiovascular.elpub.ru/jour/article/view/1735антагонисты кальцияпростаноидыэпопростенолтрепростенилилопростбозентансилденафил |
| spellingShingle | T. A. Batyraliev E. Ekinsi Z. A. Niyazova-Karben D. V. Preobrazhensky S. A. Pataraya Modern pharmaceutical treatment of pulmonary arterial hypertension Кардиоваскулярная терапия и профилактика антагонисты кальция простаноиды эпопростенол трепростенил илопрост бозентан силденафил |
| title | Modern pharmaceutical treatment of pulmonary arterial hypertension |
| title_full | Modern pharmaceutical treatment of pulmonary arterial hypertension |
| title_fullStr | Modern pharmaceutical treatment of pulmonary arterial hypertension |
| title_full_unstemmed | Modern pharmaceutical treatment of pulmonary arterial hypertension |
| title_short | Modern pharmaceutical treatment of pulmonary arterial hypertension |
| title_sort | modern pharmaceutical treatment of pulmonary arterial hypertension |
| topic | антагонисты кальция простаноиды эпопростенол трепростенил илопрост бозентан силденафил |
| url | https://cardiovascular.elpub.ru/jour/article/view/1735 |
| work_keys_str_mv | AT tabatyraliev modernpharmaceuticaltreatmentofpulmonaryarterialhypertension AT eekinsi modernpharmaceuticaltreatmentofpulmonaryarterialhypertension AT zaniyazovakarben modernpharmaceuticaltreatmentofpulmonaryarterialhypertension AT dvpreobrazhensky modernpharmaceuticaltreatmentofpulmonaryarterialhypertension AT sapataraya modernpharmaceuticaltreatmentofpulmonaryarterialhypertension |